Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Next Previous
Trial Profile

A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evofosfamide (Primary) ; Doxorubicin
  • Indications Haemangiosarcoma; Kaposi's sarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Threshold Pharmaceuticals

Most Recent Events

  • 28 Jan 2023 This trial has been discontinued in Denmark (End Date: 10 May 2016) and in Poland according to European Clinical Trials Database record.
  • 09 Jan 2023 Results of post-hoc analysis assessing mpact of administration mode on adverse events (AEs) and efficacy , published in the Clinical Cancer Research.
  • 08 Jun 2021 Data (n=303) were used for a computational analysis from this trial ; radiomics features were extracted from lung metastases patients presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top